Clinical trials: Immune Checkpoint Inhibitors
Non Small Cell Lung Cancer
OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure
The aim of this clinical trial was to determine if the therapeutic cancer vaccine OSE2101 (TEDOPI) was more effective than standard chemotherapy (docetaxel or pemetrexed) in treating HLA-A2 positive patients with metastatic NSCLC…
- Trial name
- ATALANTE-1 (NCT02654587)
- Testing
- OSE2101, Docetaxel, Pemetrexed
- Where
- 78 sites in United States, Czechia and 8 more
- Volunteers
- 219 people
- Sponsor
- OSE Immunotherapeutics
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer
This phase II trial studies how well pembrolizumab and HER2Bi-armed activated T cells work in treating patients with castration resistant prostate cancer that has spread to other places in the body.
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, PSA Progression
- Trial name
- NCT03406858
- Testing
- HER2Bi-Armed Activated T Cells, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Renal Cell Carcinoma (RCC), Urothelial Carcinoma
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
This is a Phase 1b/2, open-label, multicenter study of DSP-7888 Dosing Emulsion in combination with checkpoint inhibitors (nivolumab or pembrolizumab) in adult patients with solid tumors, that consists of 2 parts: dose search…
- Conditions
- Renal Cell Carcinoma (RCC), Urothelial Carcinoma, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT03311334
- Testing
- DSP-7888 Dosing Emulsion, Nivolumab, Pembrolizumab
- Where
- 19 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Sumitomo Pharma America, Inc.
Melanoma, Uveal
Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma
The purpose of this study is to evaluate the efficacy of lenvatinib and pembrolizumab to treat metastatic uveal melanoma.
- Trial name
- NCT05308901
- Testing
- Pembrolizumab, Lenvatinib
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Providence Health & Services
Squamous Cell Carcinoma of the Head and Neck
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
This is a randomized, double-blind, multicenter, global Phase 3 study to assess the efficacy and safety of monalizumab and cetuximab, compared to placebo and cetuximab, in Participants with recurrent or metastatic head and neck…
- Trial name
- INTERLINK-1 (NCT04590963)
- Testing
- Monalizumab, Cetuximab
- Where
- 127 sites in United States, Argentina and 21 more
- Volunteers
- 370 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer, Urothelial Cancer
Study of INCB086550 in Select Solid Tumors
An open-label, nonrandomized study to evaluate the efficacy and safety of INCB086550, a first-in-class oral inhibitor of PD-L1, as initial immune checkpoint inhibitor therapy in participants with select solid tumors
- Conditions
- Non Small Cell Lung Cancer, Urothelial Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT04629339
- Testing
- INCB086550
- Where
- 20 sites in Bulgaria, Hungary and 3 more
- Volunteers
- 16 people
- Sponsor
- Incyte Corporation
Melanoma
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
The purpose of this study is to determine the initial safety profile and initial antitumor activity of the combination treatments (immune checkpoint inhibitors [nivolumab, ipilimumab] with investigational drugs [TAK-580, TAK-202…
- Trial name
- NCT02723006
- Testing
- TAK-580, TAK-202, vedolizumab
- Where
- 14 sites in United States
- Volunteers
- 22 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Uveal Melanoma With Liver Metastases
Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.
SITISVEAL stablish the hypothesis that treatment with Tislelizumab + Sitravatinib will increase the Objective Response Rate in patients with Metastatic Uveal Melanoma with liver metastases, compared with the current standard of…
- Trial name
- SITISVEAL (NCT05542342)
- Testing
- Tislelizumab, Sitravatinib
- Where
- 4 sites in Spain
- Volunteers
- 16 people
- Sponsor
- Grupo Español Multidisciplinar de Melanoma
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
This phase II clinical trial tests how well rigosertib plus pembrolizumab workings in treating patients with melanoma which cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site)…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Refractory Melanoma
- Trial name
- NCT05764395
- Testing
- Rigosertib, Pembrolizumab, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Metastatic Carcinoma
Immune Checkpoint Inhibitor and MR-guided SBRT for Limited Progressive Metastatic Carcinoma.
This is an open label single arm phase 2 clinical trial in patients with metastatic solid malignancy of any histology who have previously experienced limited progression in at least 1 and up to 5 lesions while on immune…
- Trial name
- NCT04376502
- Testing
- Radiation Therapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Baptist Health South Florida
Nonsmall Cell Lung Cancer, NSCLC
Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-200T device, concurrent with standard therapies for stage 4 NSCLC patients, following…
- Trial name
- NCT02973789
- Testing
- NovoTTF-200T, Immune checkpoint inhibitors or docetaxel
- Where
- 124 sites in United States, Austria and 16 more
- Volunteers
- 291 people
- Sponsor
- NovoCure GmbH
Non Small Cell Lung Cancer Metastatic
Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer
This study includes the additional use of radiation therapy in combination immunotherapy in order to determine whether the radiation may improve the response of non-small cell lung cancer to immunotherapy and to monitor any side…
- Trial name
- NCT03035890
- Testing
- Radiation, Immuno-Therapeutic Agent
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- West Virginia University
Advanced Rare Malignant Solid Neoplasm, Rare Malignant Solid Neoplasm
Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial
This phase II trial tests how well atezolizumab works in combination with tiragolumab in treating patients with rare solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts…
- Conditions
- Advanced Rare Malignant Solid Neoplasm, Rare Malignant Solid Neoplasm, Refractory Rare Malignant Solid Neoplasm
- Trial name
- NCT05715281
- Testing
- Atezolizumab, Biopsy Procedure, Biospecimen Collection
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Cervix Cancer
A Study of Pembrolizumab And Platinum With Radiotherapy in Cervix Cancer
Locally advanced cervix cancers (stage 1B-IV) are usually treated with radiotherapy, concomitant cisplatin chemotherapy and brachytherapy.
- Trial name
- PAPAYA (NCT03144466)
- Testing
- Pembrolizumab
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Mesothelioma, Pleural Mesothelioma
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
Patients with pleural mesothelioma (PM) that cannot be surgically removed will receive standard chemotherapy (cisplatin or carboplatin and pemetrexed) given with durvalumab, a type of immunotherapy, or a treatment chosen by the…
- Conditions
- Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma
- Trial name
- DREAM3R (NCT04334759)
- Testing
- Durvalumab, Standard Chemotherapy, Ipilimumab and Nivolumab
- Where
- 57 sites in United States, Australia and 1 more
- Volunteers
- 214 people
- Sponsor
- PrECOG, LLC.
Histologically or Cytologically Confirmed Pancreatic Cancer, Unresectable or Borderline Resectable Pancreatic Cancer
Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer
Background: Fewer than 10 percent of people with pancreas cancer can have surgery. Surgery gives the best outcome. Radiation therapy is usually used to make surgery possible. But it does not work for most people.
- Conditions
- Histologically or Cytologically Confirmed Pancreatic Cancer, Unresectable or Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Cancer
- Trial name
- NCT04327986
- Testing
- M7824, M9241, SBRT
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Renal Cell
A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment
This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of atezolizumab given in combination with cabozantinib versus cabozantinib alone in participants with inoperable, locally…
- Trial name
- CONTACT-03 (NCT04338269)
- Testing
- Atezolizumab, Cabozantinib
- Where
- 135 sites in United States, Argentina and 13 more
- Volunteers
- 522 people
- Sponsor
- Hoffmann-La Roche
Non Small Cell Lung Cancer, Metastasis
Pembrolizumab + Idelalisib for Lung Cancer Study
This is a phase 1b/2 study to determine the safety and effectiveness of the combination of pembrolizumab and idelalisib in NSCLC patients whose disease has stopped responding to immune therapy.
- Conditions
- Non Small Cell Lung Cancer, Metastasis, Recurrence
- Trial name
- PIL (NCT03257722)
- Testing
- Pembrolizumab, Idelalisib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Asha Nayak
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This phase I/II trial studies the side effects of durvalumab, tremelimumab and hypofractionated radiation therapy in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or that has spread…
- Trial name
- NCT03522584
- Testing
- Durvalumab, Laboratory Biomarker Analysis, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Washington
Cancer Treated With Immune-checkpoint Inhibitors
Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials (SURROGATE-ICI)
Time to next treatment or death (TNT-D) may be a patient-relevant endpoint in patients treated with immune checkpoint inhibitors. This study investigate
- Trial name
- SURROGATE-ICI (NCT03963518)
- Testing
- nivolumab monotherapy, nivolumab plus ipilimumab
- Where
- France
- Volunteers
- 631 people
- Sponsor
- Institut Bergonié